Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -2.61
- Piotroski Score 2.00
- Grade Buy
- Symbol (CVRX)
- Company CVRx, Inc.
- Price $14.75
- Changes Percentage (9.1%)
- Change $1.23
- Day Low $13.38
- Day High $14.80
- Year High $33.14
CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure (HF) with reduced ejection fraction or systolic HF. The company sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, rest of Europe, and internationally. CVRx, Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 01/23/2025
- Fiscal Year End N/A
- Average Stock Price Target $15.50
- High Stock Price Target $23.00
- Low Stock Price Target $12.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$2.48
- Trailing P/E Ratio -3.88
- Forward P/E Ratio -3.88
- P/E Growth -3.88
- Net Income $-41,199,000
Income Statement
Quarterly
Annual
Latest News of CVRX
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
CVRx Inc (CVRX) Q3 2024 Earnings Call Highlights: Revenue Surge Amid Rising Expenses
CVRx narrowed its full-year guidance due to strong performance in October and Q3 momentum. The company aims for deeper market penetration and increased utilization. Successful reimbursement wins were ...
By Yahoo! Finance | 3 weeks ago -
CVRx announces new CPT Category I codes for Barostim heart failure therapy
CVRx's Barostim therapy for heart failure symptoms receives new CPT Category I codes approved by AMA. This development will enhance reimbursement processes and expand patient access, with implementati...
By Yahoo! Finance | 1 month ago -
CVRx touts positive two-year data for heart failure neuromodulation device
CVRx has reported positive long-term data on its Barostim device for heart failure patients over 24 months, showing improvements in various physical and psychosocial measures. The device received FDA ...
By Yahoo! Finance | 2 months ago
